Summarized by Masters of Longevity from Startupticker.ch.
Clinical-stage oncology biotech closed USD 28 million to fund trials and R&D.

Key Takeaways
- Onward Therapeutics raised about USD 28 million in Series B.
- Proceeds will fund clinical programs, manufacturing, and early R&D.
- Plans include expanding Taiwan operations and pursuing a Taipei listing.



